The value of biochemical markers in the diagnostics of diabetes-related bone remodeling disorders


AIMS: to assess the effect of changes in the body in men and women with type 1 and 2 diabetes on the state of markers of bone metabolism.. Determination of the directionality of changes in serum markers of bone remodeling and bone mineral density in both sexes in this disease.

METHODS: A cross-sectional study was conducted of patients diagnosed with T1DM (n = 98) and T2DM (n = 137); control group, consisted of 82 persons. Calcitropic homons, serum markers of bone remodeling were studied in all patients.

RESULTS: the results of the evaluation of the content of markers of serum bone metabolism in patients with DM1and DM2 in comparison with the control group indicate the presence of pathological changes in the processes of bone remodeling in the form of a decrease in the bone formation marker PINP in patients with DM1 by 16%, with DM2 by 12% compared with the control and enhancement of the marker of bone resorption of b-CTx in 32% of patients with DM1 and 25% of patients with DM2; as well as inconsistency of changes in bone remodeling processes in patients with DM1, with a predominant change in bone resorption, determined in 28% of cases. Patients with DM1 had lower levels of P1NP and b-CTx, which reflects a lower bone metabolism compared to patients with DM1, regardless of age and duration of the disease.

CONCLUSIONS: the loss of bone mass in the majority of the examined patients with diabetes, is associated with the suppression of bone formation and, to a much lesser extent, of bone resorption. In this case, the values ​​of bone remodeling markers in patients with DM2 are lower than in patients with DM1. Factors such as the compensation of the glycemic profile, the duration of diabetes and the presence of diabetic nephropathy can affect bone metabolism.

About the authors

Sain Safarova

Azerbaijan Medical Univesity.

Author for correspondence.
ORCID iD: 0000-0002-7131-3878
SPIN-code: 5056-0792

Azerbaijan, Azerbaijan, Baku, AZ1022, st. Bakikhanov, 23

PhD, associated professor


  1. Yamamoto M, SugimotoT. Advanced Glycation End Products, Diabetes, and Bone Strength. Curr Osteoporos Rep. 2016; 14(6): 320–326.
  2. Liamis G, Liberopoulos E, Barkas F, Elisaf M. Diabetes mellitus and electrolyte disorders. World J Clin Cases. 2014; 16; 2(10): 488–496.
  3. Fisher A., Srikusalanukul W, Fisher L., Smith P.N. Lower serum P1NP/βCTX ratio and hypoalbuminemia are independently associated with osteoporotic nonvertebral fractures in older adults. Clin Interv Aging. 2017; 12: 1131–1140.
  4. Jørgensen HS, Winther S, Bøttcher M, Hauge E, Rejnmark L, Svensson M, Ivarsen P. Bone turnover markers are associated with bone density, but not with fracture in end stage kidney disease: a cross-sectional study. BMC Nephrol. 2017; 18: 284
  5. Jiao H., Xiao E., Graves D.T. Diabetes and Its Effect on Bone and Fracture Healing. / Curr Osteoporos Rep. 2015; 13(5): 327–335.
  6. Hinton PS. Role of reduced insulin-stimulated bone blood flow in the pathogenesis of metabolic insulin resistance and diabetic bone fragility. Medical hypotheses. 2016;93:81–86.
  7. Nakashima A, Yokoyama K, Yokoo T, Urashima M. Role of vitamin D in diabetes mellitus and chronic kidney disease. World J Diabetes. 2016; 10; 7(5): 89–100.
  8. Ling O., Rivadeneira F, Zillikens MC, Oei E. Diabetes, Diabetic Complications, and Fracture Risk. Curr Osteoporos Rep. 2015; 13(2): 106–115.

Supplementary files

There are no supplementary files to display.



Abstract - 153


Article Metrics

Metrics Loading ...


Copyright (c) 2018 Safarova S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies